DATROWAY

This brand name is authorized in United States. It is also authorized in Austria, Estonia, France, Ireland, Italy, Lithuania.

Active ingredients

The drug DATROWAY contains one active pharmaceutical ingredient (API):

1	Datopotamab deruxtecan UNII GD2OWY1DTK - DATOPOTAMAB DERUXTECAN
	Datopotamab deruxtecan is a TROP2-directed antibody-drug conjugate. The antibody is a humanised anti-TROP2 IgG1 attached to deruxtecan, a topoisomerase I inhibitor (DXd) bound by a tetrapeptide-based cleavable linker. The antibody-drug conjugate is stable in plasma. The antibody binds to TROP2 expressed on the surface of certain tumour cells. After binding, datopotamab deruxtecan undergoes internalisation into the tumour cells. Subsequently, the release of DXd results in DNA damage and apoptotic cell death via topoisomerase I inhibition.
	Read more about Datopotamab deruxtecan

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
DATROWAY Powder for concentrate for solution for infusion	MPI, EU: SmPC	European Medicines Agency (EU)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
L01FX35		L Antineoplastic and immunomodulating agents → L01 Antineoplastic agents → L01F Monoclonal antibodies and antibody drug conjugates → L01FX Other monoclonal antibodies
Discover more medicines within L01FX35

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
EE	Ravimiamet	3117349
FR	Base de données publique des médicaments	61582736
IT	Agenzia del Farmaco	052175015
LT	Valstybinė vaistų kontrolės tarnyba	1103277
US	FDA, National Drug Code	65597-801